GSK's Exdensur Approved in China for Chronic Rhinosinusitis with Nasal Polyps
Summary
China's NMPA has approved GSK's Exdensur (depemokimab) for chronic rhinosinusitis with nasal polyps (CRSwNP), making it the first and only ultra-long-acting biologic for this condition in China.
Key Events
-
NMPA Approval for Exdensur
China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for chronic rhinosinusitis with nasal polyps (CRSwNP) as an add-on therapy with intranasal corticosteroids.
-
First Ultra-Long-Acting Biologic
Exdensur is the first and only ultra-long-acting biologic approved in China for CRSwNP, offering a convenient twice-yearly dosing schedule.
-
Based on Positive Phase III Trials
The approval is supported by data from the ANCHOR-1 and ANCHOR-2 phase III trials, which demonstrated clinically meaningful and statistically significant improvements in nasal polyp size and nasal obstruction.
-
Market Expansion in China
This approval follows Exdensur's recent NMPA approval for severe asthma, further expanding its market presence and commercial potential in China for a new indication.
Analysis
This approval significantly expands the market for Exdensur in China, building on its recent approval for severe asthma. As the first and only ultra-long-acting biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) in China, Exdensur addresses a substantial unmet medical need. This development, backed by robust Phase III trial data, strengthens GSK's respiratory portfolio and is expected to positively impact the company's commercial prospects in the region.
At the time of this filing, GSK was trading at $57.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $111.4B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.